Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms

Titre officiel

A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms

Sommaire:

The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of INCB057643 as monotherapy or combination with ruxolitinib for participants with myelofibrosis and other myeloid neoplasms.

Description de l'essai

Primary Outcome:

• Number of treatment-emergent adverse events

• Overall Response Rate
• Symptom Response Rate
• Anemia response
• Duration of Anemia Response
• Rate of red blood cell (RBC) transfusion dependency
• Percentage change in Spleen Volume
• Spleen length response

Voir cet essai sur ClinicalTrials.gov